Breast Cancer Management During the COVID-19 Pandemic: The Senologic International Society Survey.
Breast cancer
COVID-19
SARS-CoV-2
clinical practices
pandemic
survey
Journal
European journal of breast health
ISSN: 2587-0831
Titre abrégé: Eur J Breast Health
Pays: Turkey
ID NLM: 101709357
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
25
01
2021
accepted:
09
03
2021
entrez:
19
4
2021
pubmed:
20
4
2021
medline:
20
4
2021
Statut:
epublish
Résumé
In early 2020, the spread of coronavirus disease-2019 (COVID-19) led the World Health Organization to declare this disease a pandemic. Initial epidemiological data showed that patients with cancer were at high risk of developing severe forms of COVID-19. National scientific societies published recommendations modifying the patients' breast cancer (BC) management to preserve, in theory, quality oncologic care, avoiding the increased risk of contamination. The Senology International Society (SIS) decided to take an inventory of the actions taken worldwide. This study investigates COVID-19-related changes concerning BC management and analyzes the will to maintain them after the pandemic, evaluating their oncological safety consequences. SIS network members participated in an online survey using a questionnaire (Microsoft Forty-five responses from 24 countries showed that screening programs had been suspended (68%); magnetic resonance imagines were postponed (73%); telemedicine was preferred when possible (71%). Surgeries were postponed: reconstructive (77%), for benign diseases (84%), and in patients with significant comorbidities (66%). Chemotherapy and radiotherapy protocols had been adapted in 28% of patients in both. Exception for telemedicine (34%), these changes in practice should not be continued. The SIS survey showed significant changes in BC's diagnosis and treatment during the first wave of the COVID-19 pandemic, but most of these changes should not be maintained. Indeed, women have fewer severe forms of COVID-19 and are less likely to die than men. The risk of dying from COVID-19 is more related to the presence of comorbidities and age than to BC. Stopping screening and delaying treatment leads to more advanced stages of BC. Only women aged over 65 with BC under treatment and comorbidities require adaptation of their cancer management.
Identifiants
pubmed: 33870120
doi: 10.4274/ejbh.galenos.2021.2021-1-4
pii: 47125
pmc: PMC8025718
doi:
Types de publication
Journal Article
Langues
eng
Pagination
188-196Subventions
Organisme : NCIPC CDC HHS
ID : U17 CE002021
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
©Copyright 2021 by Turkish Federation of Breast Diseases Associations.
Déclaration de conflit d'intérêts
Conflict of Interest: No conflict of interest was declared by the authors.
Références
Eur J Breast Health. 2020 Apr 01;16(2):83-85
pubmed: 32285026
Eur J Breast Health. 2020 Mar 25;16(2):86-88
pubmed: 32285027
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
JCO Glob Oncol. 2020 Aug;6:1298-1305
pubmed: 32795196
Breast Cancer Res. 2020 Oct 30;22(1):117
pubmed: 33126915
Breast Cancer Res Treat. 2020 Jul;182(1):239-242
pubmed: 32405915
J Infect. 2020 Jun;80(6):656-665
pubmed: 32283155
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Am J Surg. 2020 Dec 8;:
pubmed: 33317814
Anticancer Res. 2020 Dec;40(12):7119-7125
pubmed: 33288611
PLoS One. 2020 Oct 26;15(10):e0241261
pubmed: 33104715
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
Cell. 2020 Sep 17;182(6):1401-1418.e18
pubmed: 32810439
ESMO Open. 2020 Sep;5(5):e000947
pubmed: 32978251
Ann Oncol. 2020 Aug;31(8):1088-1089
pubmed: 32330541
PLoS Pathog. 2020 Apr 28;16(4):e1008520
pubmed: 32343745
Lancet Oncol. 2021 Mar;22(3):309-320
pubmed: 33493433
Eur J Breast Health. 2020 Apr 21;16(3):160-161
pubmed: 32656513
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Breast Cancer Res. 2020 May 28;22(1):55
pubmed: 32460829
Biol Sex Differ. 2020 May 25;11(1):29
pubmed: 32450906
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
ESMO Open. 2020 May;5(Suppl 3):
pubmed: 32439716
Can Assoc Radiol J. 2020 Nov;71(4):459-469
pubmed: 32452700